Genetic Variants of Xenobiotic Receptors and their Implications in Drug Metabolism and Pharmacogenetics

Lamba, Jatinder K.; Schuetz, Erin G.

doi:10.1002/9780470409107.ch9

Cited by 3 publications

(2 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CAR, PXR, and VDR are members of the nuclear receptor family that also includes FXR, LXR, RXR, and PPARα, which together participate in the complex coordinated regulation of transcription of drug metabolizing enzyme and transporter genes ( Czekaj, 2000 ; Czekaj and Skowronek, 2012 ). Genetic variants in nuclear receptors contribute to interindividual differences in response to drugs that are metabolized by CYP3A enzymes ( Lamba and Schuetz, 2008 ).…”

Section: The Cytochrome P450 Systemmentioning

confidence: 99%

How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?

et al. 2020

View full text Add to dashboard Cite

Many genetic variants in drug metabolizing enzymes and transporters have been shown to be relevant for treating psychiatric disorders. Associations are strong enough to feature on drug labels and for prescribing guidelines based on such data. A range of commercial tests are available; however, there is variability in included genetic variants, methodology, and interpretation. We herein provide relevant background for understanding clinical associations with specific variants, other factors that are relevant to consider when interpreting such data (such as age, gender, drug–drug interactions), and summarize the data relevant to clinical utility of pharmacogenetic testing in psychiatry and the available prescribing guidelines. We also highlight areas for future research focus in this field.

show abstract

Section: The Cytochrome P450 Systemmentioning

confidence: 99%

How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Dimeric complex PXR/RXR interacts with AGTTCA sequence in CYP3A1/2 genes separated by a trinucleotide spacer (DR3,, and with XREM (Xenobiotic-Response Enhancer Module) and ER6 (Everted Repeat with a 6-nucleotide spacer) in the CYP3A4 gene. PXR gene polymorphism is probably one of the reasons for varied response to pharmacotherapy and the incidence of side effects in the population (Lamba & Schuetz, 2009). …”

mentioning

confidence: 99%